MKI67 and carcinoma: However, there was a high degree of inter- and intra-observer inconsistency in the read-outs of Ki-67 (LI) in moderately differentiated (G2) carcinomas, which is particularly problematic because it is for these “intermediate” carcinomas where guidance from the carcinoma’s proliferative activity is expected for chemotherapy decisions [3, 13,1].